Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Novel Point-of-Care Platform for Accurate DOAC Quantification

Ziel

MedicQuant ApS is a Danish deep-tech company spun out of Aarhus University in 2019 to address a critical need in emergency medicine: rapid, accurate quantification of small molecules from patient blood samples.
Our initial product addresses a critical unmet need in the treatment of stroke patients who are on Direct Oral Anticoagulants (DOACs).
For these patients, the life-saving thrombolysis therapy cannot be given if DOAC concentrations are too high, due to the elevated risk of fatal intracranial bleeding. Conventional lab tests take over 40 minutes - unacceptable when every 15-minute delay raises mortality 4% and severe disability 7%. Our solution aims to deliver a fast and reliable drug concentrations that empowers clinicians to make safer, faster treatment decisions in these high-stakes scenarios.
Our patent-pending portable platform provides lab-grade accuracy in under ten minutes from a blood sample. A single-use cartridge employs novel flow-front technology, then is read by a stand-alone benchtop instrument, enabling evidence-based management of DOAC strokes within the critical time window. MedicQuant measures individual DOAC levels directly in whole blood, with no sample preparation, via an innovative point-of-care method.
Usability studies at Bispebjerg Hospital (Denmark) and University College London (UK) plus large-scale testing at University Hospital Tübingen (Germany) confirm performance; an instrument is already in use at Bispebjerg Hospital. The technology has won Best Startup (2019), EIT Health MedTech Bootcamp (2020), and an EIC Women-in-TechEU (2023) grant.
By 2030 we aim to embed our test in EU and US stroke guidelines, reach €37 million revenue, and grow to a 41-person team. We will then extend to other DOAC emergencies, additional drug classes - antibiotics, anticancer agents, immunosuppressants - and new regions.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-EIC-2026-ACCELERATOR-02

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

MEDICQUANT APS
Netto-EU-Beitrag
€ 2 494 930,38
Adresse
C/O LINE DEBOIS NIELSEN PALLE JUUL-JENSENS BOULEVARD 82
8200 AARHUS N
Dänemark
KMU
Ja
Region
Danmark Midtjylland Østjylland
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten